A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

Active:	No
Cancer Type:	Multiple Myeloma	NCT ID:	NCT03374085
Trial Phases:	Phase I Phase II	Protocol IDs:	CC-92480-MM-001 (primary) NCI-2018-00132 U1111-1205-3650 2017-001236-19
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Celgene
NCI Full Details:	http://clinicaltrials.gov/show/NCT03374085

Summary

This is an open-label, multi-center, international, Phase 1/2 study to assess the safety,
PK and efficacy of CC-92480 monotherapy and in combination with dexamethasone in subjects
with relapsed and refractory multiple myeloma (RRMM).

All eligible subjects must be previously treated with at least 3 prior regimens including
lenalidomide, pomalidomide, a proteasome inhibitor and an anti-CD38 antibody and be
refractory to their last line of therapy.

Treatment Sites in Georgia

Emory Clinic
1365 Clifton Road NE
Atlanta, GA 30322
www.emoryhealthcare.org

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.